Medical Research, Diagnostic Substances & Life Science Tools

October 21, 2016

Companies covered: Mauna Kea Technologies (OTCMKTS:MKEAY), BioTime, Inc. (AMEX:BTX), PhaseRx, Inc. (NASDAQ:PZRX), Dynatronics Corporation (NASDAQ:DYNT), Anavex Life Sciences Corp. (NASDAQ:AVXL), Cellectis S.A. (NASDAQ:CLLS), Digipath, Inc. (OTCMKTS:DIGP), EDAP TMS S.A. (NASDAQ:EDAP), BioSig Technologies Inc (OTCMKTS:BSGM), DelMar Pharmaceuticals Inc (NASDAQ:DMPI), Pressure BioSciences Inc. (OTCMKTS:PBIO), Clearside Biomedical Inc (NASDAQ:CLSD), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Aimmune Therapeutics Inc (NASDAQ:AIMT), DBV Technologies S.A. (NASDAQ:DBVT), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Tobira Therapeutics Inc. (NASDAQ:TBRA), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), United Therapeutics Corporation (NASDAQ:UTHR), Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), Allergan, Inc. (NYSE:AGN), Edwards Lifesciences Corporation (NYSE:EW), Medtronic, Inc. (NYSE:MDT), ABIOMED, Inc. (NASDAQ:ABMD), Wright Medical Group, Inc. (NASDAQ:WMGI), DexCom, Inc. (NASDAQ:DXCM), Insulet Corporation (NASDAQ:PODD), ResMed Inc. (NYSE:RMD)

Buy ($175)